AAAAAA

   
Results: 1-8 |
Results: 8
Management of testicular cancer - 16 years' experience from southwest Finland
Authors: Sundstrom, J Salminen, E Nurmi, M Toppari, J Pollanen, P Pelliniemi, LJ Huhtala, S Rajala, P Laato, M
Citation: J. Sundstrom et al., Management of testicular cancer - 16 years' experience from southwest Finland, SC J UROL N, 35(1), 2001, pp. 21-25
Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users
Authors: Backman, T Huhtala, S Blom, T Luoto, R Rauramo, I Koskenvuo, M
Citation: T. Backman et al., Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users, BR J OBST G, 107(3), 2000, pp. 335-339
Docetaxel, a promising novel chemotherapeutic agent in advanced breast cancer
Authors: Salminen, E Bergman, M Huhtala, S Jekunen, A Ekholm, E
Citation: E. Salminen et al., Docetaxel, a promising novel chemotherapeutic agent in advanced breast cancer, ANTICANC R, 20(5C), 2000, pp. 3663-3668
Prognostic value of the expression of tumor suppressor genes p53, p21, p16and pRb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy
Authors: Kirla, R Salminen, E Huhtala, S Nuutinen, J Talve, L Haapasalo, H Kalimo, H
Citation: R. Kirla et al., Prognostic value of the expression of tumor suppressor genes p53, p21, p16and pRb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy, J NEURO-ONC, 46(1), 2000, pp. 71-80
Docetaxel: Standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - A phase II single-center study
Authors: Salminen, E Bergman, M Huhtala, S Ekholm, E
Citation: E. Salminen et al., Docetaxel: Standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - A phase II single-center study, J CL ONCOL, 17(4), 1999, pp. 1127-1131
Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect - Integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs
Authors: Scheinin, H Helminen, A Huhtala, S Gronroos, P Bosch, JA Kuusela, T Kanto, J Kaila, T
Citation: H. Scheinin et al., Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect - Integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs, THER DRUG M, 21(2), 1999, pp. 141-151
Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition
Authors: Rouru, J Gordin, A Huupponen, R Huhtala, S Savontaus, E Korpela, K Reinikainen, K Scheinin, M
Citation: J. Rouru et al., Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition, EUR J CL PH, 55(6), 1999, pp. 461-467
A double-blind study of MPV-2213ad, a novel aromatase inhibitor, in healthy male subjects
Authors: Ahokoski, O Irjala, K Huhtala, S Salminen, E Scheinin, H Huupponen, R
Citation: O. Ahokoski et al., A double-blind study of MPV-2213ad, a novel aromatase inhibitor, in healthy male subjects, EUR J CL PH, 55(1), 1999, pp. 27-34
Risultati: 1-8 |